Program
SYS6040
A development code. Also written as “SYS6040 for injection”.
Its studies are mostly in Small Cell Lung Carcinoma, led by CSPC Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 11 open or running | phase 1since Apr 2, 2025 | Apr 2, 2025 | Feb 28, 2027phase 1 · NCT06970795 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 2, 2025First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT06970795 · 180 planned · China
Ahead
- Feb 28, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT06970795
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06970795Small Cell Lung Carcinoma · China | 1 | Recruiting | Feb 28, 2027 | 180 |
How it is read
Names in the registry
- “SYS6040 for injection”, 1 entry
Codes read as this program: SYS6040.
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.